Oleksandra Kaskun

Oleksandra Kaskun

Auto-generated profile, based on publicly available information

Oleksandra Kaskun

The Arthur and Sonia Labatt Brain Tumor Research Center, Hospital for Sick Children, Toronto, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2019 in Cancer Research
Verified
Journal Article
Closed access
RSRohit Sachdeva
Rohit Sachdeva
MWMegan Wu
Megan Wu
SSSandra Smiljanic
Sandra Smiljanic
OKOleksandra Kaskun
Oleksandra Kaskun
KGKimia Ghannad-Zadeh
Kimia Ghannad-Zadeh
SDSunit Das
Sunit Das
Glioblastoma is the most common primary brain tumor in adults. While the introduction of temozolomide chemotherapy has increased long-term survivorship, treatment failure and rapid tumor recurrence remains universal. The transcriptional regulatory protein, inhibitor of DNA-binding-1 (ID1), is a key regulator of cell phenotype in cancer. We show that CRISPR-mediated knockout of ID1 in glioblastoma cells, breast adenocarcinoma cells, and melanoma cells dramatically reduced tumor progression in all three cancer systems through transcriptional downregulation of EGF, which resulted in decreased EGFR phosphorylation. Moreover, ID1-positive cells were enriched by chemotherapy and drove tumor recurrence in glioblastoma. Addition of the neuroleptic drug pimozide to inhibit ID1 expression enhanced the cytotoxic effects of temozolomide therapy on glioma cells and significantly prolonged time to tumor recurrence. Conclusively, these data suggest ID1 could be a promising therapeutic target in patients with glioblastoma. Significance: These findings show that the transcriptional regulator ID1 is critical for glioblastoma initiation and chemoresistance and that inhibition of ID1 enhances the effect of temozolomide, delays tumor recurrence, and prolongs survival.

31 March 2023
Verified
Other
Open access
RSRohit Sachdeva
Rohit Sachdeva
MWMegan Wu
Megan Wu
SSSandra Smiljanic
Sandra Smiljanic
OKOleksandra Kaskun
Oleksandra Kaskun
KGKimia Ghannad-Zadeh
Kimia Ghannad-Zadeh
SDSunit Das
Sunit Das
Glioblastoma is the most common primary brain tumor in adults. While the introduction of temozolomide chemotherapy has increased long-term survivorship, treatment failure and rapid tumor recurrence remains universal. The transcriptional regulatory protein, inhibitor of DNA-binding-1 (ID1), is a key regulator of cell phenotype in cancer. We show that CRISPR-mediated knockout of ID1 in glioblastoma cells, breast adenocarcinoma cells, and melanoma cells dramatically reduced tumor progression in all three cancer systems through transcriptional downregulation of EGF, which resulted in decreased EGFR phosphorylation. Moreover, ID1-positive cells were enriched by chemotherapy and drove tumor recurrence in glioblastoma. Addition of the neuroleptic drug pimozide to inhibit ID1 expression enhanced the cytotoxic effects of temozolomide therapy on glioma cells and significantly prolonged time to tumor recurrence. Conclusively, these data suggest ID1 could be a promising therapeutic target in patients with glioblastoma.Significance:These findings show that the transcriptional regulator ID1 is critical for glioblastoma initiation and chemoresistance and that inhibition of ID1 enhances the effect of temozolomide, delays tumor recurrence, and prolongs survival.

31 March 2023
Verified
Other
Open access
RSRohit Sachdeva
Rohit Sachdeva
MWMegan Wu
Megan Wu
SSSandra Smiljanic
Sandra Smiljanic
OKOleksandra Kaskun
Oleksandra Kaskun
KGKimia Ghannad-Zadeh
Kimia Ghannad-Zadeh
SDSunit Das
Sunit Das
(A) Representative H&E images of control and ID1 KO mouse brains. (B) ID1 KO mice demonstrated greater accumulation of TMEM within the brain tissues compared to control animals. TMEM-positive cells were diffusely distributed throughout the brain, while in the control group. The boxes indicate the areas shown at higher magnification. (C) Quantification of positive TMEM cells in the brain relative to area. **P<0.005 Western blot analysis shows successful gene knockout clone for ID1 protein expression in (D) MDA-MB231 and (E) A375 cells.

31 March 2023
Verified
Other
Open access
RSRohit Sachdeva
Rohit Sachdeva
MWMegan Wu
Megan Wu
SSSandra Smiljanic
Sandra Smiljanic
OKOleksandra Kaskun
Oleksandra Kaskun
KGKimia Ghannad-Zadeh
Kimia Ghannad-Zadeh
SDSunit Das
Sunit Das
(A) Flow chart of patient sample analysis (B) Representative images of IHC staining for ID1 expression in a TMA cohort. Images of weak and strong intensity staining for tumor tissues are shown. (C) Representative qPCR analysis of ID1 expresssion in U251 cells. Cells were treated with 100uM TMZ for indicated timepoints. *P>0.1

31 March 2023
Verified
Other
Open access
RSRohit Sachdeva
Rohit Sachdeva
MWMegan Wu
Megan Wu
SSSandra Smiljanic
Sandra Smiljanic
OKOleksandra Kaskun
Oleksandra Kaskun
KGKimia Ghannad-Zadeh
Kimia Ghannad-Zadeh
SDSunit Das
Sunit Das
(A) TMZ IC50 curves for U251 control and U251.TR cells. (B) U251 and U251.TR cells colony forming assay at different concentrations of TMZ. (C) Western blot analysis for EGFR and p-EGFR-1068 from lysates of U251and U251.TR cells.

31 March 2023
Verified
Other
Open access
RSRohit Sachdeva
Rohit Sachdeva
MWMegan Wu
Megan Wu
SSSandra Smiljanic
Sandra Smiljanic
OKOleksandra Kaskun
Oleksandra Kaskun
KGKimia Ghannad-Zadeh
Kimia Ghannad-Zadeh
SDSunit Das
Sunit Das
(A) Western blot analysis for the identification of two clones lacking ID1 protein expression, consistent with successful gene knockout by CRISPR. (B) DNA sequence analysis of chosen clones. Red boxes mark the sgRNA target sequence and denote predicted cut-site. (C) Cell viability was measured using Alamar Blue in a time-dependent manner. (D) Cells were cultured for 48h followed by staining with propidium iodide for flow cytometric analysis. Bar chart shows quantification of the cell cycle distribution.